News und Analysen

Sarepta Therapeutics (NASDAQ: SRPT) is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving

Managed care health insurance company Centene Inc. (NYSE: CNC) recently saw its share rebound after reaffirming its guidance. This move came just after UnitedHealth Group Inc. (NYSE: UNH) made

Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through

Risk tolerance varies from person to person. Some people have no fear of parachuting out of an airline, while others won’t even ride a rollercoaster at a theme park. Everyone is a combination of

Health insurance companies in the medical sector have not fared well in 2024. Medicare Advantage (MA) plans were a bountiful source of income until the second half of 2023. Humana Inc. (NYSE: HUM)

Shares of Medtronic (NYSE: MDT) are falling following its FQ4 release and guidance, opening up a potential buying opportunity. The question is whether its value, yield, balance sheet and cash flow

Integrated healthcare retailer and insurer CVS Health Co. (NYSE: CVS) stock presents a value not seen in years. The medical sector giant saw its shares punished on its Q1 2024 top and bottom line

The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the

Shares of AbbVie (NYSE: ABBV) fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira

Biopharma giant Pfizer Inc. (NYSE: PFE) has given back all its COVID gains and more. Shareholders have sat through a painful two-year selloff from the stock's $61.71 high on December 20, 2021, to

AbbVie Inc. (NYSE: ABBV) stock is recovering after falling over 4% in the week preceding its earnings report on April 26, 2024. As the market closed on Monday, April 29, ABBV stock posted a gain

Abbott Laboratories' (NYSE: ABT) share price was corrected at the end of CQ1 2024 on growth, profitability and capital returns concerns. The FQ1 results, however, belie the fear and have the market

UnitedHealth Group's (NYSE: UNH) Q1 results were better than expected for two reasons: First, the stock price is now rebounding from long-term lows and deep value territory with ample upside

The popular iShares Biotechnology ETF (NASDAQ: IBB) has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout. 

The bullish

DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to

The global obesity epidemic has reached unprecedented proportions, causing severe health consequences and placing an immense economic burden on healthcare systems.  Pharmaceutical companies are

As the market continues its relentless ascent to new heights, propelled by the surging tech sector and hype surrounding AI,  the murmurs of potential interest rate cuts by the Federal Reserve

Medical device maker Medtronic PLC (NYSE: MDT) is a Dividend Aristocrat in the medical and healthcare sectors. The medical device maker has raised its dividend payout for 46 consecutive years